Detail of the clinical trial
| Title of the trial | ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: A randomized phase II study of the EORTC Brain Tumor Group. |
|---|---|
| EudraCT number | 2014-004438-24 |
| Protocol number | M14-483 |
| Sponsor | AbbVie Deutschland, GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany |
| Indications | Oncology |
| Diagnosis | glioblastoma multiforme |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2015 |
| Date of approval by Institute (SÚKL) | 25.9.2015 |
| Date of approval by EC | 13.10.2015 |
| Date of initiation CT in ČR | 12.1.2016 |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
Fakultní nemocnice v Motole, Onkologicka klinika, V Úvalu 84, 150 06 Praha Fakultní nemocnice Hradec Králové, Klinika onkologie a radioterapie, Sokolská 581, 500 05 Hradec Králové Masarykův onkologický ústav, Žlutý kopec 7, 656 53 Brno Fakultní nemocnice Ostrava, Onkologická klinika, 17. listopadu 1790, 708 52 Ostrava-Poruba |
cz